Some prostaglandins are potent hypotensive agents, and the liver and lungs are important sites for their inactivation in animals.' Although the importance of this function in human liver is not known, it seemed possible that raised blood prostaglandin levels could accompany massive hepatic necrosis and contribute to the hypotension commonly found in patients with fulminant hepatic failure (FHF).2 We have therefore measured plasma levels of prostaglandin-like material in nine patients with FHF, all of whom were in grade IV coma3 and seven had been treated 12-18 hours previously with haemoperfusion through a column of coated charcoal.3 Five were. hypotensive and four were normotensive. We also investigated possible removal of prostaglandins by'a charcoal column during' haemoperfusion in four patients. Qnly one patient (No 5 .in the table) had undergone peritoneal dialysis before the blood samples were taken.
Methods and results
Blood samples from nght atrial or peripheral arterial catheters, and from the input and output lines: to the charcoal column, were put into litium heparin tubes containing indomethacin (1O4Ag/ml). Plasma levels of prostaglandin-like activity were not raised in patients with fulninant hepatic failure and appeared similar in hypotensive and normotensive subjects
Discussion
The normal levels of plasma prostaglandin-like activity found in patients with FHF suggests that if prostaglandin E or F compounds were released into the circulation they were adequately metabolised in sites other than the liver (for example, the lungs'). Prostaglandin A compounds are also potent hypotensive agents possibly occurring in blood, but unlike E-type and F-type prostaglandins they substantially resist inactivation by the lungs.-5 We cannot comment on the possibility that they contributed to the hypotension, since low levels are not detected by the rat stomach assay. Previous charcoal haemoperfusion would seem unlikely to produce lowered prostaglandin levels several hours later, and low plasma levels were also found in the two unperfused patients. Although the mean level was lower in the blood leaving the coated-charcoal column than in the blood entering it, the difference was not statistically significant. Nevertheless, only four patients were studied, and paired measurements were made after only a single pass through the column.
The present results suggest that plasma levels of prostaglandin E or F compounds are not raised in patients with FHF, and are not responsible for the hypotension and low peripheral resistance commonly seen.
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Case history
The patient, a retired schoolmaster, aged 65, was admitted to another hospital in April 1972 for investigation of diarrhoea. He had been taking 250 mg mefenamic acid three times a day since 1970 for osteoarthritis and glyceryl trinitrate for angina since 1968. Clinical examination showed only haemorrhoids. The faecal fat output was 43 g over 5 days and a barium enema showed a stricture of the sigmoid colon associated with diverticular disease. Nothing abnormal was found at laparotomy. He was discharged without change in his therapy. In October 1973 he was readmitted because of persisting diarrhoea. The faecal fat was 49-6 g over 3 days. He was treated empirically with Lomotil and pancreatic enzyme supplements.
In September 1974 his bowel actions were up to 10 a day with pale, offensive stools. He was admitted to the Manchester Royal Infirmary. Treatment with mefenamic acid, glyceryl trinitrate, Pancrex (16 tablets daily), and Lomotil (10 tablets daily) was continued. Investigations confirmed the presence of steatorrhoea' with a 3-day faecal fat output of 38 g. The results of the investigation of the following were normal: haemoglobin; serum iron, folate, Bl2, calcium, albumin; xylose tolerance test; jejunal biopsy (both histological appearance and disaccharidase levels); barium meal, follow through, and barium enema. All drug therapy was discontinued, including mefenamic acid, and within two days the diarrhoea ceased. The faecal fat output two weeks later was normal at 12 9 g in 3 days. The patient remained well after discharge. He started taking glyceryl trinitrate again without a recurrence of diarrhoea. He refused a controlled challenge with mefenamic acid.
Comment
Steatorrhoea as a complication of mefenamic acid treatment should be considered in all cases presenting with diarrhoea, which is a common and well-recognised adverse reaction. In the case reported here studies of jejunal morphology and enzymology were normal, and implies that mefenamic acid may impair the intraluminal phase of fat absorption by acting like neomycin in causing bile salt precipitation2 or inhibition of lipase activity.3
